Wall Street Zen upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN - Free Report) from a hold rating to a buy rating in a research report report published on Saturday morning.
Supernus Pharmaceuticals Stock Down 0.1%
Shares of NASDAQ:SUPN traded down $0.02 during trading on Friday, reaching $33.12. 461,128 shares of the company's stock traded hands, compared to its average volume of 487,537. Supernus Pharmaceuticals has a fifty-two week low of $27.05 and a fifty-two week high of $40.28. The firm has a market cap of $1.85 billion, a PE ratio of 29.84 and a beta of 0.70. The company has a 50-day simple moving average of $32.26 and a 200-day simple moving average of $33.76.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in shares of Supernus Pharmaceuticals by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 6,150,759 shares of the specialty pharmaceutical company's stock valued at $222,411,000 after buying an additional 22,852 shares during the period. Armistice Capital LLC increased its holdings in Supernus Pharmaceuticals by 7.4% in the 1st quarter. Armistice Capital LLC now owns 5,196,000 shares of the specialty pharmaceutical company's stock valued at $170,169,000 after purchasing an additional 360,000 shares during the last quarter. Geode Capital Management LLC increased its holdings in Supernus Pharmaceuticals by 1.9% in the 4th quarter. Geode Capital Management LLC now owns 1,510,568 shares of the specialty pharmaceutical company's stock valued at $54,633,000 after purchasing an additional 28,517 shares during the last quarter. GW&K Investment Management LLC increased its holdings in Supernus Pharmaceuticals by 14.6% in the 1st quarter. GW&K Investment Management LLC now owns 1,382,441 shares of the specialty pharmaceutical company's stock valued at $45,275,000 after purchasing an additional 176,091 shares during the last quarter. Finally, American Century Companies Inc. increased its holdings in Supernus Pharmaceuticals by 9.2% in the 4th quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company's stock valued at $41,248,000 after purchasing an additional 95,777 shares during the last quarter.
About Supernus Pharmaceuticals
(
Get Free Report)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
Recommended Stories
Before you consider Supernus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Supernus Pharmaceuticals wasn't on the list.
While Supernus Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.